Virucidal pilot study of Nasodine® Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.
ANZCTR; 14/04/2020; TrialID: ACTRN12620000470998
Clinical Trial Register
| ICTRP | ID: ictrp-ACTRN12620000470998
ABSTRACT
Condition
COVID-19 Positive;COVID-19 Positive;Infection - Other infectious diseases;Respiratory - Other respiratory disorders / diseases
Intervention
Intervention is an aqueous buffered solution of 0.5% povidone-iodine (PVP-I) contained in a 30 mL bottle closed with a traditional nasal spray pump.Subjects will receive a single dose to their nasal passages, administered by the investigator.
The amount a subject receives consists of 6 x 140µL pump actuations (3 into each nostril), being 0.84 mL total volume.
Primary outcome:
Impact of Nasodine on the reduction in virus in the nasal passages of subjects who are shedding the virus. Virus concentration is measured by PCR analysis of cell culture medium 96 hours after inoculation with a post-treatment nasal swab and compared to an equivalent culture inoculated with swab collected prior to treatment.[Endpoint is swab taken 5 minutes after dosing and compared against a swab taken 5 minutes prior to dosing.]Criteria
Inclusion criteria Adult (18+ years old) patients with(a) confirmed COVID-19 symptoms and
(b) symptom onset within the past five days.
Exclusion criteria • Known iodine sensitivity
• Previously diagnosed thyroid disease
• Previously diagnosed kidney disease
• Known to be pregnant or currently breastfeeding
Collection:
Clinical trial registers
Database:
ICTRP
Topics:
Vaccines
Year:
2020
Document Type:
Clinical Trial Register
Similar
MEDLINE
...
LILACS
LIS